Amylyx Soars 63% to 52-Week High on Avexitide Phase 3 Win and $350M Offering
AMLX has more than doubled off its 52-week low of $7.63 on elevated volume (12× avg).
Summary
Amylyx shares surged 63% to a 52-week high of $35.39 after avexitide met the primary endpoint in the Phase 3 LUCIDITY trial, showing a 55% reduction in hypoglycemic events. The company also announced a $350 million public offering with a $52.5 million underwriters' option to fund the commercial launch. An NDA submission to the FDA is expected by end of 2026, and enrollment in the Phase 1 LUMINA trial for AMX0114 in ALS has completed. This follows the positive Phase 3 results and offering announcement from August 18, adding the market's strong reaction and new pipeline milestones. AtriCure (ATRC) also hit a 52-week high on solid Q2 revenue growth, but Amylyx is the primary mover here.
At the time of this announcement, AMLX was trading at $35.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $7.63 to $35.39. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: dpa-AFX.